Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge

References

• ThomasGSTammelinBRSchiffmanGLSafety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial)J Nucl Cardiol200815331932818513638
   PubMed Web of Science ®Google Scholar
• DoukkyRPharmacologic stress testing in myocardial perfusion imaging: technical applicationsHellerGVMannAHendelRCNuclear Cardiology: Technical ApplicationsNew YorkMcGraw-Hill2007107124
   Google Scholar
• WuJCYunJJHellerENLimitations of dobutamine for enhancing flow heterogeneity in the presence of single coronary stenosis: implications for technetium-99m-sestamibi imagingJ Nucl Med19983934174259529285
   PubMed Web of Science ®Google Scholar
• Lexiscan® (regadenoson) injection for intravenous use [package insert]Northbrook, ILAstellas Pharma US2013
   Google Scholar
• GarciaCHeffernanAJSanchez de MoraEComparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthmaEur J Nucl Med Mol Imaging201441111912523857459
   PubMed Web of Science ®Google Scholar
• GeleijnseMLElhendyAFiorettiPMRoelandtJRDobutamine stress myocardial perfusion imagingJ Am Coll Cardiol20003672017202711127435
   PubMed Web of Science ®Google Scholar
• GeleijnseMLFiorettiPMRoelandtJRMethodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiographyJ Am Coll Cardiol19973035956069283514
   PubMed Web of Science ®Google Scholar
• AMR/Arlington Medical Resources IncMyocardial Perfusion Monthly Monitor112012
   Google Scholar
• GhimireGHageFGHeoJIskandrianAERegadenoson: a focused updateJ Nucl Cardiol201320228428823229649
   PubMed Web of Science ®Google Scholar
• IskandrianAEBatemanTMBelardinelliLADVANCE MPI InvestigatorsAdenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trialJ Nucl Cardiol200714564565817826318
   PubMed Web of Science ®Google Scholar
• MahmarianJJCerqueiraMDIskandrianAERegadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trialJACC Cardiovasc Imaging20092895996819679284
   PubMed Web of Science ®Google Scholar
• KwonDHCerqueiraMDYoungRLessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patientsJ Nucl Cardiol201017585385720414756
   PubMed Web of Science ®Google Scholar
• ThompsonRCRegadenoson stress in patients with asthma and COPD: a breath of fresh airJ Nucl Cardiol201219464764822527804
   PubMed Web of Science ®Google Scholar
• ZoghbiGJIskandrianAESelective adenosine agonists and myocardial perfusion imagingJ Nucl Cardiol201219112614122130964
   PubMed Web of Science ®Google Scholar
• OrlandiCPharmacology of coronary vasodilation: a brief reviewJ Nucl Cardiol199636 Pt 2S27S308989684
   PubMed Web of Science ®Google Scholar
• TrochuJNZhaoGPostHSelective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imagingJ Cardiovasc Pharmacol200341113213912500031
   PubMed Web of Science ®Google Scholar
• ZhaoGLinkeAXuXComparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogsJ Pharmacol Exp Ther2003307118218912954805
   PubMed Web of Science ®Google Scholar
• PrennerBMBukofzerSBehmSFeahenyKMcNuttBEA randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary diseaseJ Nucl Cardiol201219468169222484721
   PubMed Web of Science ®Google Scholar
• Al JaroudiWIskandrianAERegadenoson: a new myocardial stress agentJ Am Coll Cardiol200954131123113019761931
   PubMed Web of Science ®Google Scholar
• GaoZLiZBakerSPNovel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonistsJ Pharmacol Exp Ther2001298120921811408544
   PubMed Web of Science ®Google Scholar
• CerqueiraMDNguyenPStaehrPUnderwoodSRIskandrianAEADVANCE-MPI Trial InvestigatorsEffects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial resultsJACC Cardiovasc Imaging20081330731619356442
   PubMed Web of Science ®Google Scholar
• Astellas Pharma USLexiscan Product Monograph2012 http://www.lexiscan.com/pdf/Product_Monograph.pdfAccessed December 29, 2013
   Google Scholar
• GemignaniASAbbottBGThe emerging role of the selective A2A agonist in pharmacologic stress testingJ Nucl Cardiol201017349449720221857
   PubMed Web of Science ®Google Scholar
• LieuHShryockJvon MeringGRegadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humansJ Nucl Cardiol200714451452017679059
   PubMed Web of Science ®Google Scholar
• GordiTFrohnaPSunHLWolffABelardinelliLLieuHA population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteersClin Pharmacokinet200645121201121217112296
   PubMed Web of Science ®Google Scholar
• GordiTBlackburnBLieuHRegadenoson pharmacokinetics and tolerability in subjects with impaired renal functionJ Clin Pharmacol200747782583317585115
   PubMed Web of Science ®Google Scholar
• DoukkyRMorales DemoriRJainSKiriakosRMwansaVCalvinJEAttenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. “The ASSUAGE trial”J Nucl Cardiol201219344845722395779
   PubMed Web of Science ®Google Scholar
• DoukkyRRangelMODickRWassoufMAlqaidAMargetaBAttenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease: the ASSUAGE-CKD trialInt J Cardiovasc Imaging20132951029103723224354
   PubMed Web of Science ®Google Scholar
• DoukkyRRangelMOWassoufMDickRAlqaidAMorales DemoriRThe safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluationJ Nucl Cardiol201320220521323239416
   PubMed Web of Science ®Google Scholar
• AnanthasubramaniamKWeissRMcNuttBKlaukeBFeahenyKBukofzerSA randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney diseaseJ Nucl Cardiol201219231932922259009
   PubMed Web of Science ®Google Scholar
• LeakerBRO’ConnorBHanselTTSafety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trialJ Nucl Cardiol200815332933618513639
   PubMed Web of Science ®Google Scholar
• HusainZPalaniGCabreraRHemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patientsInt J Cardiovasc Imaging20122871841184922200931
   PubMed Web of Science ®Google Scholar
• HenzlovaMJCerqueiraMDMahmarianJJYaoSSQuality Assurance Committee of the American Society of Nuclear CardiologyStress protocols and tracersJ Nucl Cardiol2006136e80e9017174798
   PubMedGoogle Scholar
• ThomasGSMiyamotoMIShould simultaneous exercise become the standard for adenosine myocardial perfusion imaging?Am J Cardiol2004942A3D10D discussion 10D–11D
   Google Scholar